医学
肺癌
临床终点
放化疗
养生
肿瘤科
放射治疗
内科学
肺
临床试验
作者
Caressa Hui,Eleanor Brown,Samantha Wong,Millie Das,Heather A. Wakelee,Joel W. Neal,Kavitha Ramchandran,Nathaniel J. Myall,Daniel Pham,Lei Xing,Yong Yang,Nataliya Kovalchuk,Ying Yuan,Ying Lü,Michael Xiang,Alex Chin,Maximilian Diehn,Billy W. Loo,Lucas K. Vitzthum
标识
DOI:10.1016/j.cllc.2023.11.004
摘要
IntroductionPrior attempts to escalate radiation dose for non–small cell lung cancer (NSCLC) have not improved survival. Given the high risk for cardiopulmonary toxicity with treatment and heterogenous presentation of locally advanced NSCLC, it is unlikely that a single dose regimen is optimal for all patients. This phase I/II trial aims to evaluate a novel treatment approach where the level of accelerated hypofractionation is determined by the predicted toxicity from dose to organs at risk (OARs).MethodsPatients ≥ 18 years old with lung cancer planned for fractionated radiotherapy to the lung with concurrent chemotherapy will be eligible. Radiation therapy (RT) will be delivered to a total dose of 60 to 66 Gy in 30, 25, or 20 fractions depending on the ability to meet constraints to key organs at risk including the lungs, heart, and esophagus. The primary endpoint is high grade pulmonary, esophageal, or cardiac toxicity. A Bayesian optimized design is used to determine stopping boundaries and evaluate the primary endpoint.ConclusionPACER will evaluate the safety and feasibility of personalized accelerated chemoradiotherapy for lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI